Neurology research at Biogen is focused on identifying novel therapeutic approaches for  devastating neurological and neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) (known as Motor Neurone Disease (MND) in the UK and Ireland) and multiple sclerosis (MS), aiming to move drug candidates into human clinical testing as safely, quickly and efficiently as possible.

Internally and with our many academic partners, we have a major focus on target discovery and validation using human stem cell models, functional cell-based screening, gene network and expression analysis and study of disease-resistant neuronal populations. We functionally validate candidate targets in the most relevant models and seek evidence of their involvement in human disease.

Subsequently, we explore with our colleagues across Biogen the therapeutic modality — small molecules, antisense oligonucleotides, antibodies or biologics — best suited to the patient population we are seeking to help. Our aim for each target is to create a complete package of information based on high-level mechanistic biology and rigorous testing that will give the programme the best chance of success as it moves toward the clinic.